查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008489

类淀粉沉积症治疗市场：依治疗方法、给药途径、药物类别、类淀粉沉积症类型及最终用户划分－2026年至2032年全球市场预测

Amyloidosis Treatment Market by Treatment Type, Route Of Administration, Drug Class, Amyloidosis Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年类淀粉沉积症治疗市场价值为 61.3 亿美元，预计到 2026 年将成长至 65.9 亿美元，复合年增长率为 7.56%，到 ​​2032 年将达到 102.1 亿美元。

主要市场统计数据
基准年 2025 61.3亿美元
预计年份：2026年 65.9亿美元
预测年份 2032 102.1亿美元
复合年增长率 (%) 7.56%

全面概述了目前类淀粉沉积症治疗领域的最新诊断进展、扩展的治疗方法和不断发展的护理路径。

类淀粉沉积症曾是一种罕见且易误诊的疾病，如今已发展成为一个治疗领域，其特点是诊断技术的快速进步和标靶治疗的蓬勃发展。近年来，临床医生和研究人员受益于生物标记检测、影像学技术以及透过多学科协作改进的诊疗路径，从而实现了更早期的检测和更精准的表型分析。这些临床进展为更有效地实施治疗性介入和更详细地追踪患者预后提供了契机。

标靶分子疗法、早期检测和不断发展的医疗保健服务模式如何重新定义类淀粉沉积症的临床和商业性重点。

过去十年，类淀粉沉积症的治疗格局发生了翻天覆地的变化，这主要得益于标靶分子疗法的出现、诊断演算法的改进以及临床实践模式的重塑。 TTR 抑制剂和稳定器的出现重新定义了 ATTR 亚型淀粉样变性的治疗目标，为直接调控潜在致病级联反应提供了治疗方法。同时，AL类淀粉沉积症的单株抗体疗法改变了标准的诱导治疗方案，并为先前对标准治疗无效的患者拓展了治疗选择。

评估 2025 年美国关税变化对类淀粉沉积症变性治疗中药品供应链、筹资策略和患者取得途径的多方面影响。

2025年实施的贸易政策发展和关税调整进一步增加了美国医药和生物製药供应链相关人员的营运复杂性。累积关税措施，特别是那些影响关键进口商品（例如活性药物成分、特种化学品和某些成品生物製药）的措施，正在加剧本已采用准时生产模式、库存极低的供应链的成本压力。不断上涨的投入成本正推高製造商的成本结构，迫使他们重新评估其分销、采购和定价策略。

将治疗方法、分子分类、给药途径、临床环境和疾病亚型与商业性和临床决策联繫起来的细分市场主导洞察。

对市场细分的详细分析揭示了临床需求、商业性机会和营运风险的交汇点。根据治疗类型，整体情况包括药物治疗、干细胞移植和支持治疗。药物治疗方案进一步细分为烷化剂、免疫调节剂、单株抗体、蛋白酶体抑制剂、TTR 沉默剂和 TTR 稳定剂。这些分类的例子包括Melphalan（烷化剂）、来那度胺（免疫调节剂）、Lenalidomide（单株抗体）、Daratumumab佐米、Carfilzomib和Bortezomib（蛋白酶体抑制剂）、Ixazomib和帕替西兰（TTR 沉默剂）以及阿可拉米迪和他法米迪（TTR 稳定剂）。根据给药途径，治疗方法可采用静脉注射、口服和皮下注射，每种途径对物流、用药依从性和临床实施环境的影响各不相同。

影响全球类淀粉沉积症变性治疗区域诊断、报销途径、供应链韧性和部署计画的区域差异。

区域趋势持续影响医疗服务的可近性、投资和临床实践，因此需要采取因地制宜的策略。在美洲，高度专业化的医疗中心集中分布，且历来拥有雄厚的创新资金筹措支持，从而促进了新疗法和诊断技术的快速应用。然而，公立和私立医疗体系之间不同的支付政策导致病患就医和报销时间存在差异。相较之下，欧洲、中东和非洲地区的情况则更为复杂，实行单一支付系统的地区能够提供更为标准化的就医途径，而其他市场则由于基础设施的限制，在推广高成本治疗方法进展缓慢。

大型製药企业的规模、生物技术创新、诊断领域的合作以及生产策略的相互作用，如何决定它们在类淀粉沉积症领域的竞争地位？

类淀粉沉积症领域的竞争格局由大型製药企业、专业生物技术公司、契约製造和诊断公司组成，它们共同努力，为创新和药物可及性创造了充满活力的环境。拥有完善商业基础设施的成熟製药公司在扩大已通过核准治疗方法的覆盖范围和谈判复杂的医保报销协议方面发挥着至关重要的作用，而灵活的生物技术公司则往往在下一代抑製剂、稳定剂和靶向生技药品的早期创新方面发挥着主导作用。

为类淀粉沉积症领域的製造商、支付方和医疗保健提供者制定可操作的策略重点，以改善可及性、确保供应弹性并展现可持续的临床价值。

产业领导者应采取多管齐下的策略，在不断变化的政策和供应挑战下，充分发挥临床价值并维持药物可及性。优先投资诊断基础设施和临床医生教育至关重要，这有助于透过促进早期检测和准确的亚型鑑定来提高疾病修正治疗的临床效用。同时，应制定循证方案，将随机对照试验数据和可操作的真实世界数据相结合，以支持与支付方开展有效的价值对话，并降低处方药在不同报销环境下的风险。

结合临床专家见解、公开监管记录和系统文献综述的稳健混合方法研究途径，可以得出基于证据的结论。

本分析整合了第一手和第二手研究方法，旨在全面展现临床、商业性和营运趋势。第一手研究包括对关键意见领袖（KOL）进行结构化访谈，访谈对象涵盖血液科医生、循环系统科医生、神经科医生、专科诊所主任和采购负责人，以及与行业高管进行对话，以深入了解产品线开发和商业化策略的背景资讯。第二手研究包括对同行评审的临床文献、监管核准和适应症更新、临床试验註册数据以及上市公司资讯披露进行系统性回顾，并辅以对最新诊断指南和支付方政策公告的检验。

概述了将诊断技术进步、治疗方法多样化和创新与对患者产生更广泛影响所需的策略措施。

总之，类淀粉沉积症治疗领域正进入一个诊断技术进步与治疗方法多样化相融合的新阶段，为改善患者预后和实现策略性商业性成长创造了切实机会。临床医生现在可以使用更多种类的缓解疾病药物和辅助疗法，医疗保健系统也正在调整其服务模式以适应慢性病管理路径。贸易政策的变化和供应链压力凸显了製定具有韧性的筹资策略的必要性，而区域差异则要求制定因地制宜的市场准入和循证实践计划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：类淀粉沉积症治疗市场（依治疗方法划分）

  • 药物治疗
    • 烷化剂
    • 免疫调节剂
    • 单株抗体
    • 蛋白酶体抑制剂
      • Bortezomib
      • Carfilzomib
      • 伊沙佐米
    • TTR消音器
      • 伊诺特森
      • 糕点师
    • TTR稳定器
      • 阿科拉米迪斯
      • 塔法米迪斯
  • 干细胞移植
  • 支持性护理

第九章类淀粉沉积症治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十章：类淀粉沉积症治疗市场：依药物类别划分

  • 烷化剂
  • 免疫调节剂
  • 单株抗体
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米
  • TTR消音器
    • 伊诺特森
    • 糕点师
  • TTR稳定器
    • 阿科拉米迪斯
    • 塔法米迪斯

第十一章类淀粉沉积症治疗市场（依类淀粉沉积症类型划分）

  • AA
  • AL
  • 遗传性ATTR
  • 野生型 ATTR

第十二章类淀粉沉积症治疗市场：依最终用户划分

  • 居家照护
  • 医院
  • 专科诊所

第十三章类淀粉沉积症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章类淀粉沉积症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章类淀粉沉积症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国类淀粉沉积症治疗市场

第十七章：中国类淀粉沉积症治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbvie, Inc.
  • Acrotech Biopharma, Inc
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals Inc.
  • Arcturus Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Attralus, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Neurimmune AG
  • Oncopeptides AB
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation PLC
  • Regeneron Pharmaceuticals Inc.
  • SOM INNOVATION BIOTECH, SA,
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market was valued at USD 6.13 billion in 2025 and is projected to grow to USD 6.59 billion in 2026, with a CAGR of 7.56%, reaching USD 10.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.13 billion
Estimated Year [2026] USD 6.59 billion
Forecast Year [2032] USD 10.21 billion
CAGR (%) 7.56%

Comprehensive orientation to recent diagnostic precision, therapeutic expansion, and evolving care pathways shaping amyloidosis management today

Amyloidosis has evolved from a rare, often misdiagnosed condition into a therapeutic area marked by rapid diagnostic refinement and a proliferation of targeted treatments. In recent years, clinicians and researchers have benefited from improved biomarker assays, imaging modalities, and multidisciplinary care pathways that together enable earlier detection and more precise phenotyping. These clinical advances create opportunities for therapeutic interventions to be deployed more effectively and for patient outcomes to be tracked with greater granularity.

Concurrently, the treatment toolkit has expanded across multiple modalities. Pharmacological treatments encompass a range of approaches from classic alkylating agents to next-generation TTR silencers and stabilizers, while autologous stem cell transplantation remains a curative-intent option for eligible patients. Supportive therapies continue to play a pivotal role in symptom control and quality-of-life enhancement, particularly as disease-modifying agents extend survival and shift focus toward long-term management. As a result, care delivery models are adapting to balance specialist-driven hospital care, outpatient specialty clinics, and increasing home-based services.

This introduction frames the broader executive summary by emphasizing the interplay between diagnostics, therapeutic innovation, and care delivery. It sets the stage for deeper analysis of market dynamics, regulatory pathways, and stakeholder strategies that follow, while underscoring the importance of integrating clinical evidence with commercial planning to capitalize on emerging opportunities and to address persistent access challenges.

How targeted molecular therapies, earlier detection, and evolving care delivery models are collectively redefining clinical and commercial priorities in amyloidosis

Over the past decade, the amyloidosis landscape has experienced transformative shifts driven by targeted molecular therapies, improved diagnostic algorithms, and a recalibration of clinical practice patterns. The arrival of TTR silencers and stabilizers has reframed treatment goals for ATTR subtypes, bringing therapies that directly modulate the underlying pathogenic cascade. At the same time, monoclonal antibody approaches for AL amyloidosis have changed standard induction regimens and expanded options for patients who were previously refractory to conventional regimens.

Diagnostic progress, including more sensitive cardiac imaging and refined biomarkers, has enabled clinicians to identify amyloid subtypes earlier and to stratify patients by risk with greater confidence. This earlier detection translates into heightened demand for interventions that can alter disease trajectory rather than simply palliate symptoms, and it increases the importance of care coordination across cardiology, neurology, hematology, and specialized clinics. Parallel to therapeutic and diagnostic advances, payer and regulatory environments have adapted by creating more robust pathways for accelerated approvals and conditional access programs, although reimbursement negotiations remain complex in many jurisdictions.

Finally, health systems and providers are adapting delivery models to accommodate chronic management needs. There is a visible shift toward integrating home-based infusion and monitoring where clinically appropriate, and toward specialty clinic hubs that concentrate expertise and facilitate rapid initiation of complex therapies. These systemic shifts are collectively reshaping investment priorities, R&D focus, and commercial strategies across the ecosystem.

Assessing the multifaceted effects of 2025 United States tariff changes on pharmaceutical supply chains, procurement strategies, and patient access in amyloidosis care

Trade policy developments and tariff adjustments instituted in 2025 have introduced another layer of complexity for stakeholders operating in the United States pharmaceutical and biologics supply chains. Cumulative tariff measures, particularly those affecting key import categories such as active pharmaceutical ingredients, specialty chemicals, and certain finished biologics components, have increased the cost pressure on supply chains that are already operating with lean inventories and just-in-time manufacturing approaches. These elevated input costs exert upward pressure on manufacturers' cost structures and force reassessment of distribution, procurement, and pricing strategies.

Beyond direct cost impacts, tariffs can induce shifts in sourcing decisions and contractual terms. Companies may accelerate nearshoring or diversify supplier bases to mitigate exposure to tariff volatility, while contract manufacturers reassess capacity commitments and lead times. In tandem, payers and integrated delivery networks may respond to rising acquisition costs by intensifying value-based contracting discussions, demanding clearer real-world evidence of clinical benefit and long-term outcomes. For smaller biotech firms, the financial strain of increased input costs and elongated supply chains can slow clinical development timelines and complicate commercialization plans.

Clinicians and patients can also experience indirect effects: sporadic supply disruptions or pricing pressures may constrain access to specialized formulations or result in prioritization schemes by providers. In response, resilient companies are investing in supply chain visibility tools, multi-sourcing agreements, and strategic inventory buffers to preserve continuity of care while maintaining competitive positioning. Regulatory engagement and public-private dialogue remain important levers to ensure essential therapies maintain stable availability despite broader trade policy shifts.

Segment-driven insights that link therapeutic modality, molecular class, administration route, care setting, and disease subtype to commercial and clinical decision-making

A granular view of segmentation illuminates where clinical needs intersect with commercial opportunity and operational risk. Based on treatment type, the therapeutic landscape encompasses pharmacological treatment, stem cell transplantation, and supportive therapy, with pharmacological options further categorized into alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, TTR silencers, and TTR stabilizers; examples within these classes include melphalan among alkylating agents, lenalidomide among immunomodulators, daratumumab within monoclonal antibodies, bortezomib, carfilzomib and ixazomib among proteasome inhibitors, and inotersen and patisiran representing TTR silencers while acoramidis and tafamidis exemplify TTR stabilizers. Based on route of administration, therapies span intravenous, oral, and subcutaneous delivery, each of which imposes distinct logistical, adherence, and site-of-care implications for deployment.

Examining end users, care is delivered across home care settings, hospitals, and specialty clinics, and each channel shapes product design, patient support needs, and reimbursement pathways. Based on drug class segmentation, the overlap between pharmacological taxonomy and molecular mechanism highlights where therapeutic substitution or combination strategies are clinically plausible. Finally, by amyloidosis type including AA, AL, hereditary ATTR, and wild-type ATTR, clinical presentation and progression differ markedly, which in turn influence the suitability of transplantation, the selection of disease-modifying agents, and the emphasis on supportive care.

Taken together, this segmentation matrix supports targeted product development, precision commercial approaches, and differentiated patient support models. It also informs clinical trial design by clarifying endpoints and subgroup stratification that resonate with regulatory reviewers and payer assessments.

Nuanced regional considerations affecting diagnostics, reimbursement pathways, supply chain resilience, and adoption timelines across global amyloidosis care geographies

Regional dynamics continue to shape access, investment, and clinical practice in ways that require tailored strategies. In the Americas, concentrated centers of excellence and a historically aggressive innovation funding environment support rapid adoption of novel therapeutics and diagnostic technologies, but divergent payer policies across public and private systems create variability in patient access and reimbursement timelines. In contrast, the Europe, Middle East & Africa region presents a heterogeneous mosaic where single-payer jurisdictions may enable more standardized adoption pathways while other markets face infrastructural constraints that delay diffusion of high-cost therapies.

Asia-Pacific markets exhibit a mix of rapid biopharmaceutical manufacturing expansion and diverse regulatory approaches; several countries within the region are building local production capabilities and regulatory frameworks that aim to both attract clinical development activity and lower dependence on external supply chains. Across regions, variations in diagnostic capacity, specialist availability, and local treatment guidelines influence how rapidly new modalities move from approval to routine care. In low-resource settings, supportive care and symptom management often remain the immediate priorities, while high-resource systems increasingly emphasize long-term disease modification and integrated care models.

Strategic entrants must therefore align commercialization, medical affairs, and supply strategies to regional nuances. This includes adapting value demonstration dossiers to local evidence requirements, investing in clinician education where diagnostic literacy remains nascent, and establishing manufacturing or sourcing partnerships to reduce tariff and logistics exposure while accelerating time to patient.

How the interplay between big pharma scale, biotech innovation, diagnostics partnerships, and manufacturing strategies is determining competitive positioning in amyloidosis

Competitive activity across the amyloidosis space reflects a mix of large pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and diagnostics firms that together shape the innovation and access landscape. Established pharmaceutical companies with broad commercial infrastructures play a pivotal role in scaling approved therapies and negotiating complex reimbursement arrangements, while nimble biotech firms tend to drive early-stage innovation in next-generation silencers, stabilizers, and targeted biologics.

Strategic partnerships and licensing agreements have become central to accelerating clinical development and market entry. Collaborations between therapy developers and diagnostics providers are increasingly important to ensure accurate patient identification and to support companion diagnostic strategies that underpin value-based contracting. Contract manufacturing organizations and regional producers also play a critical role by offering capacity to mitigate tariff exposure and to enable localized supply chains that reduce lead times for critical therapies.

Investors and potential partners should monitor pipeline progression, regulatory milestones, and evidence-generation strategies that differentiate products in terms of clinical benefit and real-world applicability. Companies that demonstrate robust post-approval evidence collection, invest in patient support services, and proactively engage payers and clinician networks are better positioned to translate clinical promise into sustainable adoption across diverse care settings.

Actionable strategic priorities for manufacturers, payers, and providers to enhance access, ensure supply resilience, and demonstrate sustained clinical value in amyloidosis

Industry leaders should adopt a multi-pronged approach to capture clinical value and to sustain access amidst evolving policy and supply challenges. Prioritize investments in diagnostic infrastructure and clinician education to drive earlier detection and appropriate subtype assignment, thereby increasing the clinical utility of disease-modifying therapies. Concurrently, design evidence-generation plans that combine randomized data with pragmatic real-world evidence to support robust value conversations with payers and to de-risk formulary inclusion across different reimbursement environments.

Reinforce supply chain resilience through supplier diversification, selective nearshoring, and strategic inventory buffers for critical inputs. Negotiate flexible contractual terms with suppliers and logistics partners to accommodate tariff volatility and to preserve continuity of care. Align product development with route-of-administration preferences for targeted patient cohorts, recognizing that oral and subcutaneous formulations can expand home-based care opportunities while intravenous regimens often require hospital or clinic resources.

Finally, cultivate partnerships across the ecosystem-including diagnostics providers, specialty clinics, and patient advocacy groups-to build comprehensive care pathways that improve adherence, monitor outcomes, and support long-term disease management. Embrace outcome-based contracting where feasible, and invest in digital tools that enable remote monitoring and patient engagement, thereby strengthening the real-world case for therapeutic value and enabling more predictable reimbursement conversations.

Robust mixed-methods research approach combining clinical expert insights, public regulatory records, and systematic literature review to ensure evidence-driven conclusions

This analysis synthesizes primary and secondary research methods to deliver a balanced view of clinical, commercial, and operational dynamics. Primary research comprised structured interviews with key opinion leaders including hematologists, cardiologists, neurologists, specialty clinic directors, and procurement executives, combined with dialogues with industry executives to contextualize pipeline developments and commercialization strategies. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory approvals and label updates, clinical trial registries, and public company disclosures, augmented by an examination of diagnostic guideline updates and payer policy announcements.

Data triangulation ensured that clinical findings align with observed commercial behaviors and supply chain realities. Qualitative insights from expert interviews were cross-validated with published trial outcomes and regulatory documentation to mitigate bias and to refine interpretations. Analytical techniques included thematic synthesis for qualitative inputs and comparative trend mapping to highlight regional and segment-level differences. The methodology prioritized transparency in assumptions and explicitly excluded speculative market sizing or forecasting to maintain focus on actionable intelligence and evidence-based recommendations.

Concluding synthesis of diagnostic advances, therapeutic diversification, and strategic actions required to translate innovation into broader patient impact

In conclusion, the amyloidosis landscape is entering a phase where diagnostic sophistication and therapeutic diversity converge to create tangible opportunities for improved patient outcomes and strategic commercial growth. Clinicians now have access to a wider array of disease-modifying agents and supportive strategies, and health systems are recalibrating care delivery to accommodate chronic management pathways. Trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies, while regional heterogeneity demands tailored market entry and evidence-generation plans.

For stakeholders across the ecosystem, the path forward involves aligning clinical innovation with pragmatic access mechanisms and operational preparedness. By investing in diagnostics, forging strategic partnerships, and collecting meaningful real-world evidence, organizations can bridge the gap between clinical potential and widespread patient benefit. The recommendations contained herein provide a roadmap for navigating the evolving therapeutic, regulatory, and commercial environment surrounding amyloidosis treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyloidosis Treatment Market, by Treatment Type

  • 8.1. Pharmacological Treatment
    • 8.1.1. Alkylating Agents
    • 8.1.2. Immunomodulators
    • 8.1.3. Monoclonal Antibodies
    • 8.1.4. Proteasome Inhibitors
      • 8.1.4.1. Bortezomib
      • 8.1.4.2. Carfilzomib
      • 8.1.4.3. Ixazomib
    • 8.1.5. TTR Silencers
      • 8.1.5.1. Inotersen
      • 8.1.5.2. Patisiran
    • 8.1.6. TTR Stabilizers
      • 8.1.6.1. Acoramidis
      • 8.1.6.2. Tafamidis
  • 8.2. Stem Cell Transplantation
  • 8.3. Supportive Therapy

9. Amyloidosis Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Amyloidosis Treatment Market, by Drug Class

  • 10.1. Alkylating Agents
  • 10.2. Immunomodulators
  • 10.3. Monoclonal Antibodies
  • 10.4. Proteasome Inhibitors
    • 10.4.1. Bortezomib
    • 10.4.2. Carfilzomib
    • 10.4.3. Ixazomib
  • 10.5. TTR Silencers
    • 10.5.1. Inotersen
    • 10.5.2. Patisiran
  • 10.6. TTR Stabilizers
    • 10.6.1. Acoramidis
    • 10.6.2. Tafamidis

11. Amyloidosis Treatment Market, by Amyloidosis Type

  • 11.1. AA
  • 11.2. AL
  • 11.3. Hereditary ATTR
  • 11.4. Wild-Type ATTR

12. Amyloidosis Treatment Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Amyloidosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyloidosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyloidosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Amyloidosis Treatment Market

17. China Amyloidosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbvie, Inc.
  • 18.6. Acrotech Biopharma, Inc
  • 18.7. Alexion Pharmaceuticals
  • 18.8. Alnylam Pharmaceuticals Inc.
  • 18.9. Arcturus Therapeutics, Inc.
  • 18.10. Astellas Pharma, Inc.
  • 18.11. AstraZeneca PLC
  • 18.12. Attralus, Inc.
  • 18.13. BridgeBio Pharma, Inc.
  • 18.14. Bristol-Myers Squibb Company
  • 18.15. Corino Therapeutics, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Ionis Pharmaceuticals, Inc.
  • 18.18. Johnson & Johnson Services Inc
  • 18.19. Merck & Co., Inc.
  • 18.20. Neurimmune AG
  • 18.21. Oncopeptides AB
  • 18.22. Pfizer Inc.
  • 18.23. Proclara Biosciences Inc.
  • 18.24. Prothena Corporation PLC
  • 18.25. Regeneron Pharmaceuticals Inc.
  • 18.26. SOM INNOVATION BIOTECH, SA,
  • 18.27. Sorrento Therapeutics, Inc.
  • 18.28. Spectrum Pharmaceuticals, Inc.
  • 18.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 253. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 292. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 305. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED S